Targets › PHOX2B
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2032.
Involved in the development of several major noradrenergic neuron populations, including the locus coeruleus. Transcription factor which could determine a neurotransmitter phenotype in vertebrates. (UniProt, Q99453)
Open in Phaseline: the race on PHOX2B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stephan Grupp MD PhD | PHOX2B PC-CAR T Cells PHOX2B-targeting chimeric antigen receptor (CAR) T cell therapy | PHOX2B | Phase 1 | Refractory Neuroblastoma | Jun 2032 |
Refractory Neuroblastoma (1)
other (1)
Stephan Grupp MD PhD (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.